myriad
genetics
announce
quarterly
financial
results
november
salt
lake
city
globe
newswire
myriad
genetics
nasdaq
mygn
leader
molecular
diagnostics
precision
medicine
announced
hold
quarterly
earnings
conference
call
period
ending
september
investors
analysts
est
monday
november
call
paul
diaz
president
ceo
bryan
riggsbee
chief
financial
officer
provide
financial
overview
business
update
myriad
performance
quarter
number
domestic
callers
international
callers
may
dial
callers
asked
reference
reservation
number
archived
replay
call
available
seven
days
dialing
entering
reservation
number
conference
call
along
slide
presentation
available
live
webcast
myriad
genetics
myriad
genetics
leading
personalized
medicine
company
dedicated
trusted
advisor
transforming
patient
lives
worldwide
pioneering
molecular
diagnostics
myriad
discovers
commercializes
molecular
diagnostic
tests
determine
risk
developing
disease
accurately
diagnose
disease
assess
risk
disease
progression
guide
treatment
decisions
across
six
major
medical
specialties
molecular
diagnostics
significantly
improve
patient
care
lower
healthcare
costs
information
visit
company
website
myriad
myriad
logo
bart
bracanalysis
colaris
colaris
ap
mypath
myrisk
myriad
myrisk
myrisk
hereditary
cancer
mychoice
myplan
bracanalysis
cdx
tumor
bracanalysis
cdx
mychoice
cdx
vectra
prequel
foresight
genesight
riskscore
prolaris
trademarks
registered
trademarks
myriad
genetics
wholly
owned
subsidiaries
united
states
foreign
countries
